Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

Latest Prostate Cancer News

No Survival Benefit With Cabozantinib in Progressive mCRPC

No Survival Benefit With Cabozantinib in Progressive mCRPC

Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.

Metastatic Prostate Cancer Cases Increasing

Metastatic Prostate Cancer Cases Increasing

Research emphasizes the need for nationwide refinements in the prostate cancer screening process.

PD-1 Blockade Shows Promise for mCRPC

PD-1 Blockade Shows Promise for mCRPC

In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.

Prostate Multiparametric MRI Feasible for PCa Screening

Prostate Multiparametric MRI Feasible for PCa Screening

Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.

Robot-Assisted Prostate Surgery Safe, Effective Long Term

Robot-Assisted Prostate Surgery Safe, Effective Long Term

Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.

Familial Risk of Aggressive Prostate Cancer Quantified

Familial Risk of Aggressive Prostate Cancer Quantified

Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.

Prostate Cancer Patients Taking Statins Lived Longer

Prostate Cancer Patients Taking Statins Lived Longer

Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

PI3K Pathway Aberrations May Reveal Targeted Therapy Opportunities

Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

Benign Tissue Changes May Help Predict Post-RP Biochemical Recurrence

Preliminary findings suggest a field effect in prostate cancer.

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Australian Docs Less Favorable to Post-RP Adjuvant Radiation Therapy

Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.

Expectant Management for PCa More Likely at Academic Centers

Expectant Management for PCa More Likely at Academic Centers

Odds of using this strategy are 2.7-fold greater vs community facilities.

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

Inherited Mutations Common Among Men With Metastatic Prostate Cancer

Genetic testing results could help guide therapy for advanced prostate cancer.

Hypofractionated RT Noninferior for Localized Prostate Cancer

Hypofractionated RT Noninferior for Localized Prostate Cancer

For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

Lymphovascular Invasion Helps Predict Post-RP Biochemical Recurrence

About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.

Prostate Cancer Diagnoses Decreased From 2011 to 2013

Prostate Cancer Diagnoses Decreased From 2011 to 2013

Use of active surveillance increasing, active treatment decreasing for low-risk disease.

Prostate Cancer Videos

Sign up for free e-Newsletters